GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) ConventionGlobeNewsWire • 10/02/19
Global Blood Therapeutics: Stock Responds To Voxelotor Receiving Priority ReviewSeeking Alpha • 09/09/19
GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 09/05/19
GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 09/03/19
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics ConferenceGlobeNewsWire • 09/03/19
The Totality Of Voxelotor Phase 3 Data Increases My Conviction In Global Blood TherapeuticsSeeking Alpha • 07/29/19
Global Blood Therapeutics: Voxelotor Can Take The Stock Price To New All-Time HighsSeeking Alpha • 07/03/19
Global Blood Therapeutics' Data Falls On Deaf Ears, But Massive Potential Exists With Accelerated Approval PathwaySeeking Alpha • 06/18/19
Options Traders Expect Huge Moves in Global Blood Therapeutics (GBT) StockZacks Investment Research • 06/13/19